Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.78−0.16 (-1.61%)
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Earnings
Climb Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.18
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Climb Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$0.18 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | – | – | -$0.18 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026before the open | – | – | -$0.26 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | -$0.31 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025during market hours | – | – | -$0.13 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | – | – | -$0.13 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | – | – | -$1.81 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 20, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | – | – | -$0.84 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023during market hours | – | – | -$0.29 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | -$0.37 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | – | – | -$0.56 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.50 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 7, 2022during market hours | – | – | -$0.40 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021during market hours | – | – | -$0.70 | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 13, 2021during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Climb Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Climb Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Climb Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- Results
- Results
- Update
- Update
- News
- Results
- Update
- News
See a number that looks wrong?